FAS antibody (Fas (TNF Receptor Superfamily, Member 6)) (FITC)

Details for Product anti-FAS Antibody No. ABIN5541251
Antigen
  • ALPS1A
  • APO-1
  • APT1
  • CD95
  • FAS1
  • FASTM
  • TNFRSF6
  • FASL
  • TNFSF6
  • AI196731
  • APO1
  • TNFR6
  • Tnfrsf6
  • lpr
  • Fas cell surface death receptor
  • Fas ligand
  • tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Fas (TNF receptor superfamily member 6)
  • FAS
  • FASLG
  • YWHAZ
  • Fas
  • fas
Alternatives
anti-Human FAS antibody for Immunohistochemistry (Paraffin-embedded Sections)
Reactivity
Human
640
109
95
4
3
2
2
1
1
1
Host
Mouse
372
329
19
4
4
3
Clonality (Clone)
Monoclonal ()
Conjugate
This FAS antibody is conjugated to FITC
67
57
45
28
16
9
8
8
7
7
7
7
4
4
4
4
4
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Application
Flow Cytometry (FACS)
322
294
206
153
82
71
69
65
52
38
19
16
11
8
7
6
3
3
3
2
2
2
1
1
Options
Immunogen Recombinant human Fas
Clone UB2
Isotype IgG1
Specificity This antibody recognizes the human Fas antigen specifically. Clone UB2 does not recognize the mouse Fas antigen.
Purification Protein A agarose
Plasmids, Primers & others Plasmids, Primers & others FAS products on genomics-online (e.g. as negative or positive controls)
Antigen
Alternative Name cd95,fas (FAS Antibody Abstract)
Background It is now widely accepted that apoptosis plays an important role in the selection of immature thymocytes and Ag-primed peripheral T cells. Fas antigen is a cell-surface protein that mediates apoptosis. It is expressed in various tissues including the thymus and has structural homology with a number of cell-surface receptors, includin g tumor necrosis factor receptor and nerve growth factor receptor.
UniProt P25445
Pathways p53 Signaling, Apoptosis, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity
Application Notes Flow cytometry: 20 μL (ready for use). For details see protocol below.
Protocol Flow cytometric analysis for floating cells We usually use Fisher tubes or equivalents as reaction tubes for all steps described below. 1) Wash the cells 3 times with washing buffer [PBS containing 2 % fetal calf serum (FCS) and 0.1 % NaN 3]. 2) Resuspend the cells with washing buffer (5 x 10 6 cells/mL). 3) Add 50 μ L of the cell suspension into each tube, and centrifuge at 500 x g for 1 minute at room temperature (20~25 o C). Remove supernatant by careful aspiration. 4) Add 20 μ L of Clear Back (human Fc receptor blocking reagent) to the cell pellet after tapping. Mix well and incubate for 5 minutes at room temperature. 5) Add 20 μ L of FITC labeled anti-Fas monoclonal antibody (UB2). Mix well and incubate for 30 minutes at room temperature. 6) Add 1 mL of the washing buffer followed by centrifugation at 500 x g for 1 minute at room temperature. Remove supernatant by careful aspiration. 7) Resuspend the cells with 500 μ L of the washing buffer and analyze by a flow cytometer. (Positive control for Flow cytometry transfectant)
Restrictions For Research Use only
Format Liquid
Buffer 0.09 % NaN 3 Stabilizers: 1 % BSA
Storage 4 °C
Storage Comment Store at 2-8 °C. Shelf life: one year from despatch.
Expiry Date 12 months
Product cited in: Mezosi, Wang, Utsugi, Bajnok, Bretz, Gauger, Thompson, Baker: "Induction and regulation of Fas-mediated apoptosis in human thyroid epithelial cells." in: Molecular endocrinology (Baltimore, Md.), Vol. 19, Issue 3, pp. 804-11, 2005 (PubMed).

Hauptschein, Sloan, Torella, Moezzifard, Giel-Moloney, Zehetmeier, Unger, Ilag, Jay: "Functional proteomic screen identifies a modulating role for CD44 in death receptor-mediated apoptosis." in: Cancer research, Vol. 65, Issue 5, pp. 1887-96, 2005 (PubMed).

Vega, Jazirehi, Huerta-Yepez, Bonavida et al.: "Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and ..." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 4, pp. 2174-83, 2005 (PubMed).

Suhara, Fukuo, Yasuda, Tsubakimoto, Takemura, Kawamoto, Yokoi, Mogi, Kaimoto, Ogihara: "Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways." in: Hypertension, Vol. 43, Issue 6, pp. 1208-13, 2004 (PubMed).

Suhara, Kim, Kirshenbaum, Walsh: "Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation." in: Molecular and cellular biology, Vol. 22, Issue 2, pp. 680-91, 2001 (PubMed).

Sata, Suhara, Walsh: "Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy." in: Arteriosclerosis, thrombosis, and vascular biology, Vol. 20, Issue 2, pp. 309-16, 2000 (PubMed).

Shinohara, Yagita, Ikawa, Oyaizu: "Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation." in: Cancer research, Vol. 60, Issue 6, pp. 1766-72, 2000 (PubMed).

Kuwano, Miyazaki, Hagimoto, Kawasaki, Fujita, Kunitake, Kaneko, Hara: "The involvement of Fas-Fas ligand pathway in fibrosing lung diseases." in: American journal of respiratory cell and molecular biology, Vol. 20, Issue 1, pp. 53-60, 1999 (PubMed).

Hiromatsu, Hoshino, Yagita, Koga, Sakisaka, Honda, Yang, Kayagaki, Okumura, Nonaka: "Functional Fas ligand expression in thyrocytes from patients with Graves' disease." in: The Journal of clinical endocrinology and metabolism, Vol. 84, Issue 8, pp. 2896-902, 1999 (PubMed).

Dai, Price, Brunner, Krantz: "Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis." in: Blood, Vol. 91, Issue 4, pp. 1235-42, 1998 (PubMed).

Boirivant, Pica, DeMaria, Testi, Pallone, Strober: "Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis." in: The Journal of clinical investigation, Vol. 98, Issue 11, pp. 2616-22, 1997 (PubMed).

Ando, Hiroishi, Kaneko, Moriyama, Muto, Kayagaki, Yagita, Okumura, Imawari: "Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 158, Issue 11, pp. 5283-91, 1997 (PubMed).

Hata, Matsuzaki, Takeya, Yoshida, Sonoki, Nagasaki, Kuribayashi, Kawano, Takatsuki: "Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders." in: Blood, Vol. 86, Issue 5, pp. 1939-45, 1995 (PubMed).

Did you look for something else?